CHMP November 2026 Recommends Seven New Medicines for Approval
November 16, 2026


The CHMP November 2026 meeting, held from 9 to 12 November, recommended seven new medicines for approval and 11 extensions of therapeutic indication. The committee also confirmed two refusals after re-examination and recorded two withdrawn applications for new medicines. EMA published its meeting highlights on 13 November 2026.
| Decision type | November 2026 | Total in 2026 |
|---|---|---|
| New medicines recommended for approval | 7 | 79 |
| Negative opinions on new medicines | 0 | 8 |
| Extensions of therapeutic indication recommended | 11 | 108 |
| Withdrawn applications for new medicines | 2 | 12 |
Source: European Medicines Agency, CHMP meeting highlights, 13 November 2026 (CHMP statistics).
CHMP November 2026 approvals
The seven new medicines comprise three new non-orphan medicines, two biosimilars and two generic or hybrid medicines. For comparison, Syenza’s coverage of the September 2026 meeting reported 12 new medicines.
| Medicine | INN | Type | Applicant | Indication |
|---|---|---|---|---|
| Aumseqa | aumolertinib | New | SFL Pharmaceuticals Deutschland GmbH | Non-small cell lung cancer in adults |
| Baxfendy | baxdrostat | New | AstraZeneca AB | Hypertension in adults (insufficiently controlled) |
| Zybrivo | sintilimab | New | Fortvita Biologics (Ireland) Limited | Non-squamous non-small cell lung cancer in adults |
| Garzulys | insulin aspart | Biosimilar | Sciencepharma Sp. z o.o. | Diabetes mellitus in adults, adolescents and children aged 1 year and above |
| Donrafylix | insulin aspart | Biosimilar | Kuraci | Diabetes mellitus in adults, adolescents and children aged 1 year and above |
| Fondaparinux sodium Evumed | fondaparinux sodium | Generic | Evumed Limited | Prevention of venous thromboembolic events, treatment of deep vein thrombosis, pulmonary embolism, unstable angina and myocardial infarction in adults |
| Ruxolitinib Krka | ruxolitinib | Generic | KRKA tovarna zdravil d.d. Novo mesto | Myelofibrosis and polycythaemia vera in adults, and graft-versus-host disease in adults and children |
Source: European Medicines Agency, CHMP meeting highlights, 13 November 2026 (positive recommendations on new medicines).
Aumseqa, Baxfendy and Zybrivo are the three new non-orphan medicines. Syenza has separately covered the US approval of baxdrostat, the active ingredient in Baxfendy. Each of the seven is listed as pending a European Commission decision.
Extensions of therapeutic indication
The CHMP recommended extending the use of Gazyvaro (obinutuzumab) to treat adults with moderate-to-severe active systemic lupus erythematosus. EMA describes the disease as an autoimmune condition that predominantly affects women, in which the immune system attacks the body’s own tissues and causes inflammation that can damage organs. According to EMA, Gazyvaro reduces disease activity and lets patients reduce their corticosteroid use and the associated risk of side effects. It is for patients whose disease is not adequately controlled by standard treatment.
The committee also adopted a positive opinion to extend the indication of Isturisa (osilodrostat) to endogenous Cushing’s syndrome in adolescents and children aged 6 years and older. Cushing syndrome is a rare disease in which the adrenal glands, two glands situated above the kidneys, produce an excess of the hormone cortisol.
The committee recommended extensions for nine more medicines already authorised in the EU: Bexsero, Cosentyx, Dovato, Enflonsia, Steglatro, Sunlenca, Talzenna, Tivicay and Welireg.
Re-examinations and withdrawals
After re-examination, the committee confirmed its recommendation to refuse marketing authorisation for two medicines. KemSu (sufentanil and ketamine) is intended for acute pain in children and adolescents. Meplyffa (arimoclomol citrate) is intended for Niemann-Pick disease type C, a rare, inherited, progressive neurodegenerative disorder, in patients aged two years and older in combination with miglustat. Meplyffa was designated an orphan medicine. EMA has published question-and-answer documents for both.
Two initial applications were withdrawn. Amlypave (anselamimab) was intended for kappa light chain amyloidosis, a disease in which protein clumps called amyloids build up in tissues and organs such as the heart. Qezzaqar (catequentinib) was intended for two types of soft tissue sarcoma. Both were designated orphan medicines.
Earlier in 2026, Anavex withdrew its blarcamesine application after CHMP feedback.
Medicines intended for use outside the EU
The CHMP recommended a new 100 mg strength of the Dapivirine Vaginal Ring, used to reduce the risk of HIV-1 infection through vaginal intercourse in women aged 16 and older. The new strength means the ring can be replaced every three months instead of every month.
The medicine was assessed under EU-M4All, a procedure that lets EMA support regulatory capacity building and contribute to protecting and promoting public health beyond the EU. Experts from the World Health Organization and national regulators in Kenya, South Africa and Zambia also took part in the assessment.
Mounjaro and oral contraceptives
The CHMP adopted a direct healthcare professional communication (DHPC) on the potential effect of Mounjaro (tirzepatide) on the reliability of oral contraceptives. The DHPC reminds healthcare professionals that contraception is recommended for women who can become pregnant and use Mounjaro.
Limited information is available on the effect of tirzepatide on the pharmacokinetics and efficacy of oral contraceptives in women with obesity, overweight or type 2 diabetes mellitus. Women using an oral contraceptive are now advised to either add a barrier method of contraception for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase, or switch to a non-oral method of contraception.
Mounjaro is used with diet and physical activity to treat adults with type 2 diabetes that is not satisfactorily controlled. It is also used with diet and physical activity to help people with obesity (BMI of 30 kg/m2 or more), or who are overweight (BMI between 27 and 30 kg/m2) and have weight-related health problems, lose weight and keep it under control.
Following a decision by the European Commission, the DHPC will be disseminated to healthcare professionals by the marketing authorisation holder. It will also be published on the EMA website and in national registers in EU Member States.
Source: European Medicines Agency, meeting highlights from the Committee for Medicinal Products for Human Use, 9 to 12 November 2026 (published 13 November 2026).
Let Google know we are your trusted source.
Add our editorial as a preferred source in your search results.
Value Science Weekly
The week in health technology assessment, market access and health economics — what moved, and what it means.





